DiaMedica Therapeutics Inc.
DMAC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DMAC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1, for the treatment of preeclampsia (PE), acute ischemic stroke (AIS), and fibrotic diseases (FGR), with no approved products or revenue to date.
Key risk: No revenue or approved products
BioSniper Score
Based on 5 of 6 signals
Market Cap
$344.6M
Cash Runway
15.5 moLead Asset
DM199 (Phase 2/Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for DiaMedica Therapeutics Inc..
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1, for the treatment of preeclampsia (PE), acute ischemic stroke (AIS), and fibrotic diseases (FGR), with no approved products or revenue to date.
- DiaMedica has no commercial products and has not generated any revenue from product sales; it expects to continue incurring operating losses for at least the next few years [sec_mda · as of 2026-08-10].
- Cash and equivalents were $5.1M as of 2026-06-30 [sec]; the company expects current cash to fund planned operations for at least 12 months from the date of its most recent financial statements [sec_mda · as of 2026-08-10].
- The company is conducting a Phase 2/3 adaptive trial (ReMEDy2) in acute ischemic stroke and a global Phase 2 trial in early-onset preeclampsia [sec_mda · as of 2026-08-10].
- DiaMedica estimates the interim analysis of the ReMEDy2 trial will be completed in the first quarter of 2027 [sec_mda · as of 2026-08-10].
- The company has incurred net losses in each period since inception, with a net loss of -$10.1M for the six months ended 2026-06-30 [sec].
What works
- DiaMedica has a diversified clinical pipeline targeting preeclampsia, acute ischemic stroke, and fibrotic diseases, which may spread development risk [sec_mda · as of 2026-08-10].
- The company expects its current cash resources to be sufficient to fund planned operations for at least the next 12 months, providing a near-term operational runway [sec_mda · as of 2026-08-10].
- The ReMEDy2 trial is advancing with global site activations in the U.S. and Europe, and enrollment of additional participants [sec_mda · as of 2026-08-10].
What to weigh
- DiaMedica has no approved products and no revenue from product sales; it does not expect to generate product revenue for at least two to three years [sec_mda · as of 2026-08-10].
- The company has incurred net losses in every period since inception and expects operating losses to increase moderately as clinical programs expand [sec_mda · as of 2026-08-10].
- The ReMEDy2 trial has faced enrollment delays and difficulties in forecasting enrollment; failure to resolve these issues may cause further delays [sec_mda · as of 2026-08-10].
- Cash and equivalents of $5.1M as of 2026-06-30 [sec] is limited relative to the costs of multiple late-stage trials, and additional funding may not be available on favorable terms [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
DiaMedica has no commercial products and expects no product revenue for at least two to three years.
“We have not generated any revenues from product sales and do not expect to do so for at least two to three years.”
SEC MD&A · August 10, 2026
The company expects current cash to fund operations for at least 12 months.
“We expect our current cash resources to be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of the condensed consolidated financial statements included in this report.”
SEC MD&A · August 10, 2026
The ReMEDy2 trial interim analysis is estimated for Q1 2027.
“As we approach enrollment of the 200 th participant, we estimate that the interim analysis will be completed in the first quarter of 2027.”
SEC MD&A · August 10, 2026
DiaMedica has incurred net losses in each period since inception.
“We have incurred a net loss in each”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline — Phase 3 Topline: Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety a — Topline data from the Phase 2/3 adaptive ReMEDy2 trial in acute ischemic stroke is expected; results will inform the program's regulatory path.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — DiaMedica has no commercial products and expects no product revenue for at least two to three years [sec_mda · as of 2026-08-10].
- Clinical trial enrollment delays — The ReMEDy2 trial has faced enrollment difficulties; failure to resolve may cause further delays [sec_mda · as of 2026-08-10].
- Limited cash runway — Cash of $5.1M as of 2026-06-30 [sec] may be insufficient to complete all planned trials without additional funding [sec_mda · as of 2026-08-10].
- Dependence on DM199 success — The company's future depends entirely on the successful development and regulatory approval of DM199 [sec_mda · as of 2026-08-10].
What to watch
- Interim analysis of the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, estimated for Q1 2027 [sec_mda · as of 2026-08-10].
- Enrollment progress and site activations in the global Phase 2 preeclampsia trial and the ReMEDy2 trial [sec_mda · as of 2026-08-10].
- Any updates on additional financing or capital-raising activities, given the limited cash position [sec_mda · as of 2026-08-10].
Sources: SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run DiaMedica Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DiaMedica Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
15.5 months
D/E 0.17
Lead: Phase 2/Phase 3
2 candidates
1 upcoming, next in ~93d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
97
Total value held
$79.0M
| Holder | Shares | Value |
|---|---|---|
| cooperman leon g | 2,020,000 | $13.7M |
| blackrock, inc. | 1,856,187 | $12.6M |
| millennium management llc | 935,592 | $6.3M |
| paragon associates & paragon associates ii joint venture | 875,000 | $5.9M |
| geode capital management, llc | 780,516 | $5.3M |
| vanguard capital management llc | 666,912 | $4.5M |
| state street corp | 644,211 | $4.4M |
| first manhattan co. llc. | 455,000 | $3.1M |
| northern trust corp | 338,526 | $2.3M |
| osaic holdings, inc. | 319,675 | $2.2M |
Showing top 10 of 97 institutional holders of DiaMedica Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.6%
- Days to cover
- 26.3
- Shares short
- 4,899,610
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DMAC short interestGovernance
Frequently asked questions
What is the AI investment thesis for DiaMedica Therapeutics Inc.?
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1, for the treatment of preeclampsia (PE), acute ischemic stroke (AIS), and fibrotic diseases (FGR), with no approved products or revenue to date.
What is DiaMedica Therapeutics Inc.'s lead drug candidate?
DiaMedica Therapeutics Inc.'s most advanced tracked candidate is DM199 (Phase 2/Phase 3) for Pre-Eclampsia.
What is DiaMedica Therapeutics Inc.'s next catalyst?
DiaMedica Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety a" — expected December 1, 2026.
Who is the CEO of DiaMedica Therapeutics Inc.?
Mr. Dietrich John Pauls MBA is the chief executive officer of DiaMedica Therapeutics Inc. (DMAC).
Where is DiaMedica Therapeutics Inc. headquartered?
DiaMedica Therapeutics Inc. (DMAC) is headquartered in Minneapolis, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.